Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...

Tatsuya Yoshida, Mikito Takefuji, and Toyoaki Murohara in the Department of Cardiology, Nagoya University Graduate School of Medicine, identified an enzyme, alpha-kinase 2 (ALPK2) that is specifically ...

The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK‐M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in ...

The study investigates the prognostic impact of sex and sex‐related differences in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF). More data regarding the ...

Recently, data from several clinical trials of SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), Angiotensin-receptor neprilysin inhibitors (ARNI), and GLP-1 receptor agonists, however, ...

Obesity is quite common in patients suffering from heart failure with preserved ejection fraction (HFpEF). 1 Semaglutide is a glucagon-like peptide-1 receptor agonist that has been shown to cause ...